首页> 外国专利> New fredericamycin derivatives are topoisomerase I inhibitors useful to treat tumor, parasite, immunosupression and neurodermititis

New fredericamycin derivatives are topoisomerase I inhibitors useful to treat tumor, parasite, immunosupression and neurodermititis

机译:新的腓特烈霉素衍生物是拓扑异构酶I抑制剂,可用于治疗肿瘤,寄生虫,免疫抑制和神经性皮炎

摘要

Fredericamycin derivatives (I) and their stereoisomers, tautomers and salts are new. Fredericamycin derivatives (I) of formula (Ia) or (Ib) and their stereoisomers, tautomers and salts are new. R1 : H, 1-6C-cycloalkyl, cycloalkyl or 1-4C-alkyl-cycloalkyl; R2 : H, 1-4C-alkyl, 2-14C-alkenyl, (hetero)aryl 1-4C-alkyl-aryl, 1-4C-alkenyl-heteroaryl, (hetero)cycloalkyl, 1-4C-alkyl-cycloalkyl, C mH 2m+o-pY1 p, (CH 2) rCH 2NHCOR21, (CH 2) rCH 2OCOR21, (CH 2) rCH 2NHCSR21, (CH 2) rCH 2S(O) nR21, (CH 2) rCH 2SCOR21, (CH 2) rCH 2OSO 2-R21, (CH 2) rCHO, CH 2-O-N=CH-(het)aryl, CH 2-O-N=CH-R21, CH 2-O-N=CR21R22, CH 2-O-N=CH=cycloalkyl, CH=N-S-(het)aryl, (CH 2) rCH=NOH, (CH 2) rCH(OH)R21, (CH 2) rCH=NOR21, (CH 2) rCH=NOCOR21, (CH 2) rCH=NOCH 2CONR21R22, (CH 2) rCH=NOCH(CH 3)CONR21R22, (CH 2) rCH=NOC(CH 3) 2CONR21R22, (CH 2) rCH=N-NHCOR23, (CH 2) rCH=N-NHC(O)NH-R23, (CH 2) rCH=N-NHC(S)NH-R23, (CH 2) rCH=N-NHC(NH)NH-R23, (CH 2) rCH=N-CH 2NHCOR21, (CH 2) rCH=N-NHCS-R23, (CH 2) rCH=CR24R25 (cis or trans), (CH 2) rCOOH, (CH 2) rCOOR21, (CH 2) rCONR21R22, (CH 2) rCH=NR21, hydrazine compound of formula (1), (CH 2) rCH=N-NR21R22, (CH 2) r-long chain group such as (CH 2) rCH=N-N-(1-3C-alkyl-NX1R211R212R213); m : 1-6 (for o is 1, p is 1-2m+o), 2-6 (for o is -1, p is 1-2m+o) or 4-6 (for o is -2, p is 1-2m+o); Y1 : halo, OH, OR21, NH 2, NHR21, NR21R22, SH or SR21; X1 : NR215, O or S; R211-R215 : H, 1-6C-alkyl or (CH 2) rCH=N-NHSO 2-(hetero)aryl; r : 0-5, preferably 0; R21, R22 : 1-14C-alkyl, 1-14C-alkanoyl, 1-6C-alkylhydroxy, 1-8C-alkylamino, 1-6C-alkylamino-1-6C-alkyl, 1-6C-alkylamino-di-1-6C-alkyl, (hetero)cycloalkyl, 1-4C-alkyl-(hetero)cycloalkyl, cycloalkanoyl, 1-4C-alkyanoyl-cycloalkyl, (hetero)cycloalkanoyl, 1-4C-alkanoyl-heterocycloalkyl, 1-4C-alkanoyl-(hetero)aryl or mono-/di- sugar residue (glucuronic acid and its optical stereoisomers C-atom, aldopentose, aldohexose or its deoxy compound such as glucose, deoxyglucose, ribose or deoxyribose), which is linked by C-atom that carries a OH-group; R23 : R21, CH 2-pyridinium salt or CH 2tri-1-6C-alkylammonium-sa either R24, R25 : R21, H, CN, COCH 3, COOH, COOR21, CONR21R22, NH 2or NHCOR21; or R24+R25 : 4-8C-cyloalkyl; R3 : H, F, Cl, Br, I, OH, OR31, NO 2, NH 2, NHR31, NR31R32, NHCHO, NHCOR31, NHCOCF 3, CH 3-mhal m(where hal is Cl or F (preferred) and m is 1-3), OCOR31, SCN, CN, N 3, CH 2NR331R332, CH 2OH, CH 2OR33, CH 2SR33, 2-14C-alkyl, 2-14C-alkenyl, 2-14C-alkynyl, (hetero)aryl, 1-4C-alkyl-aryl, 1-4C-alkyl-heteroaryl (where (hetero)aryl is substituted with (hetero)aryl, 1-4C-alkyl-(hetero)aryl, O-aryl, 1-4C-alkyl-O-aryl, O-heteroayl or 1-4C-alkyl-O-heteroaryl), (hetero)cycloalkyl, 1-4C-alkyl-(hetero)cycloalkyl, C mH 2m +o-pY2 p(where m is 2-6 (for o is -1, p is 1-2m+o) or 4-6 (for o is -2, p is 1-2m+o)), CH 2NHCOR31, CH 2NHCSR31, CH 2S(O) nR31 (where n is 0-2), CH 2SCOR31, CH 2OSO 2-R31, CHO, CH=NOH, CH(OH)R31, -CH=NOR31, -CH=NOCOR31, -CH=NOCH 2CONR31R32, -CH=NOCH(CH 3)CONR31R32, -CH=NOC(CH 3) 2CONR31R32, -CH=N-NHCO-R33, -CH=N-NHCO-CH 2NHCOR31, -CH=N-O-CH 2NHCOR31, -CH=N-NHCS-R33, -CH=CR34R35 (trans or cis), COOH, COOR31, CONR31R32, -CH=NR31, -CH=N-NR31R32, hydrazine compound of formula (2), CH=N-NHSO 2-aryl, -CH=N-NHSO-2-heteroaryl, SCN, CN, N 3, CH 2NR331R332 or CH 2SR33; X2 : NR315, O or S; R311-R315 : H or 1-6C-alkyl; R331, R332 : R33; Y2 : halo, OH, OR31, NH 2, NHR31, NR31R32, SH or SR31; R31, R32 : 1-14C alkyl, 1-14C alkanoyl, 1-6C alkylhydroxy, 1-6C alkylamino, 1-6C alkylamino-1-6C-alkyl, 1-6C-alkylannino-di-1-6C-alkyl, cycloalkyl, 1-4C-alkyl-cycloalkyl, heterocycloalkyl, 1-4C-alkyl-heterocycloalkyl, aryl, aryloyl, 1-4C-alkyl-aryl, heteroaryl, heteroaryloyl, 1-4C alkyl-heteroaryl, cycloalkanoyl, 1-4C alkanoyl-cycloalkyl, heterocycloalkanoyl, 1-4C alkanoyl-heterocycloalkyl, 1-4C-alkanoyl-aryl, 1-4C-alkanoyl-heteroaryl, mono- and di- sugar residues (that are connected over carbon atom, where the sugar carries an OH group and the sugar residues are glucuronic acid and its stereoisomers at all optical carbon atoms, aldopentose, aldohexose including its deoxy compound (like glucose, deoxyglucose, ribose, deoxyribose)); R33 : R31, CH 2pyridinium salt or CH 2tri-1-6C-alkylammonmium-sa R34 : R31, H, CN, COCH 3, COOH, COOR21, CONR31R32, NH 2or NHCOR31; R35 : R31, H, CN, COCH 3, COOH, COOR31, CONR31R32, NH 2or NHCOR31; R34R35 : 4-8C cycloalkyl; R5 : H, 1-6C alkyl, cycloalkyl, 1-4C-alkyl-cycloalkyl, heterocycloalkyl, 1-4C alkyl-heterocycloalkyl, aryl, 1-4C-alkyl-aryl, heteroaryl, 1-4C-alkylheteroaryl; R4,R6,R7 : H, 1-6C alkyl or CO-R41; R41 : R21; either X : O, S, NH or N-R8; or X-R5 : H, F, Cl, Br, I, N 3or W 1-R51; either R8 : R5; or NR8R5 : 4-8 membered heterocycloalkyl ring, optionally contains further heteroatoms such as N, O or S; Y 1F, Cl, Br, I, N 3, CN, CH 2NRY3RY4, CH2OH, CH2ORY3, CH2SRY4, SCN, aryl or hetaryl; either RY3, RY4 : R23; or NRY3RY4 : 4-8 membered heterocycloalkyl ring, optionally contains further heteroatoms such as N, O or S; W 1O, S, NH or N-R81; either R81, R51 : R5; or NR81R51 : 4-8 membered heterocycloalkyl ring, optionally contains further heteroatoms such as N, O or S; Z : O, S or NR9; and R9 : H or 1-6C alkyl. [Image] [Image] ACTIVITY : Cytostatic; Antiparasitic; Immunosuppressive; Antiinflammatory; Neuroprotective. MECHANISM OF ACTION : Topoisomerase I inhibitor; Topoisomerase II inhibitor. The cytotoxic effect of (I) was tested in breast cancer cell (MCF7). The results showed that (I) exhibited median inhibitory concentration of 0.19 mu M.
机译:Fredericamycin衍生物(I)及其立体异构体,互变异构体和盐是新的。式(Ia)或(Ib)的腓特烈霉素衍生物(I)及其立体异构体,互变异构体和盐是新的。 R1:H,1-6C-环烷基,环烷基或1-4C-烷基-环烷基; R2:H,1-4C-烷基,2-14C-烯基,(杂)芳基1-4C-烷基-芳基,1-4C-烯基-杂芳基,(杂)环烷基,1-4C-烷基-环烷基,C mH 2m + o-pY1 p,(CH 2)rCH 2NHCOR21,(CH 2)rCH 2OCOR21,(CH 2)rCH 2NHCSR21,(CH 2)rCH 2S(O)nR21,(CH 2)rCH 2SCOR21,(CH 2) )rCH 2OSO 2-R21,(CH 2)rCHO,CH 2-ON = CH-(het)芳基,CH 2-ON = CH-R21,CH 2-ON = CR21R22,CH 2-ON = CH =环烷基, CH = NS-(杂)芳基,(CH 2)rCH = NOH,(CH 2)rCH(OH)R21,(CH 2)rCH = NOR21,(CH 2)rCH = NOCOR21,(CH 2)rCH = NOCH 2CONR21R22,(CH 2)rCH = NOCH(CH 3)CONR21R22,(CH 2)rCH = NOC(CH 3)2CONR21R22,(CH 2)rCH = N-NHCOR23,(CH 2)rCH = N-NHC(O) NH-R23,(CH 2)rCH = N-NHC(S)NH-R23,(CH 2)rCH = N-NHC(NH)NH-R23,(CH 2)rCH = N-CH 2NHCOR21,(CH 2 )rCH = N-NHCS-R23,(CH 2)rCH = CR24R25(顺式或反式),(CH 2)rCOOH,(CH 2)rCOOR21,(CH 2)rCONR21R22,(CH 2)rCH = NR21,肼化合物式(1)中,(CH 2)rCH = N-NR21R22,(CH 2)r-长链基团,例如(CH 2)rCH = NN-(1-3C-烷基-NX1R211R212R213); m:1-6(对于o为1,p为1-2m + o),2-6(对于o为-1,p为1-2m + o)或4-6(对于o为-2,p是1-2m + o); Y 1:卤素,OH,OR 21,NH 2,NHR 21,NR 21 R 22,SH或SR 21; X1:NR215,O或S; R211-R215:H,1-6C-烷基或(CH 2)rCH = N-NHSO 2-(杂)芳基; r:0-5,优选0; R21,R22:1-14C-烷基,1-14C-烷酰基,1-6C-烷基羟基,1-8C-烷基氨基,1-6C-烷基氨基-1-6C-烷基,1-6C-烷基氨基-二-1- 6C-烷基,(杂)环烷基,1-4C-烷基-(杂)环烷基,环烷酰基,1-4C-烷酰基-环烷基,(杂)环烷酰基,1-4C-烷酰基-杂环烷基,1-4C-烷酰基-(杂)芳基或单/二糖残基(葡萄糖醛酸及其光学立体异构体C原子,醛糖,醛糖己糖或其脱氧化合物,例如葡萄糖,脱氧葡萄糖,核糖或脱氧核糖),它们通过C原子相连,并带有OH-基团R23:R21,CH 2-吡啶鎓盐或CH 2tri-1-6C-烷基铵盐; R24,R25:R21,H,CN,COCH 3,COOH,COOR21,CONR21R22,NH 2或NHCOR21之一;或R24 + R25:4​​-8C-环烷基;或R3:H,F,Cl,Br,I,OH,OR31,NO 2,NH 2,NHR31,NR31R32,NHCHO,NHCOR31,NHCOCF 3,CH 3-mhal m(其中hal是Cl或F(优选)和m是1-3),OCOR31,SCN,CN,N 3,CH 2NR331R332,CH 2OH,CH 2OR33,CH 2SR33、2-14C-烷基,2-14C-烯基,2-14C-炔基,(杂)芳基, 1-4C-烷基-芳基,1-4C-烷基-杂芳基(其中(杂)芳基被(杂)芳基,1-4C-烷基-(杂)芳基,O-芳基,1-4C-烷基-取代O-芳基,O-杂酰基或1-4C-烷基-O-杂芳基),(杂)环烷基,1-4C-烷基-(杂)环烷基,C mH 2m + o-pY2 p(其中m为2-6 (对于o是-1,p是1-2m + o)或4-6(对于o是-2,p是1-2m + o)),CH 2NHCOR31,CH 2NHCSR31,CH 2S(O)nR31(其中n为0-2),CH 2SCOR31,CH 2OSO 2-R31,CHO,CH = NOH,CH(OH)R31,-CH = NOR31,-CH = NOCOR31,-CH = NOCH 2CONR31R32,-CH = NOCH(CH 3)CONR31R32,-CH = NOC(CH 3)2CONR31R32,-CH = N-NHCO-R33,-CH = N-NHCO-CH 2NHCOR31,-CH = NO-CH 2NHCOR31,-CH = N-NHCS-R33, -CH = CR34R35(反式或顺式),COOH,COOR31,CONR31R32,-CH = NR31,-CH = N-NR31R32,式(2)的肼化合物,CH = N- NHSO 2-芳基,-CH = N-NHSO-2-杂芳基,SCN,CN,N 3,CH 2NR331R332或CH 2SR33; X2:NR315,O或S; R311-R315:H或1-6C-烷基; R331,R332:R33; Y 2:卤素,OH,OR 31,NH 2,NHR 31,NR 31 R 32,SH或SR 31; R31,R32:1-14C烷基,1-14C烷酰基,1-6C烷基羟基,1-6C烷基氨基,1-6C烷基氨基-1-6C-烷基,1-6C-烷基亚氨基-二-1-6C-烷基,环烷基,1-4C-烷基-环烷基,杂环烷基,1-4C-烷基-杂环烷基,芳基,芳基,1-4C-烷基-芳基,杂芳基,杂芳基,1-4C烷基-杂芳基,环烷酰基,1-4C烷酰基-环烷基,杂环烷酰基,1-4C烷酰基-杂环烷基,1-4C-烷酰基-芳基,1-4C-烷酰基-杂芳基,单糖和二糖残基(在碳原子上连接,其中糖带有OH基,糖残基是葡萄糖醛酸及其在所有光学碳原子上的立体异构体,醛戊糖,醛己糖,包括其脱氧化合物(如葡萄糖,脱氧葡萄糖,核糖,脱氧核糖); R33:R31,CH 2吡啶盐或CH 2tri-1-6C-烷基铵盐; R34:R31,H,CN,COCH 3,COOH,COOR21,CONR31R32,NH 2或NHCOR31; R35:R31,H,CN,COCH 3,COOH,COOR31,CONR31R32,NH 2或NHCOR31; R34R35:4-8C环烷基; R5:H,1-6C烷基,环烷基,1-4C-烷基-环烷基,杂环烷基,1-4C烷基-杂环烷基,芳基,1-4C-烷基-芳基,杂芳基,1-4C-烷基杂芳基; R4,R6,R7:H,1-6C烷基或CO-R41; R41:R21; X:O,S,NH或N-R 8;或X-R 5:H,F,Cl,Br,I,N 3或W 1> -R51;或R8:R5;或者或NR 8 R 5:4-8元杂环烷基环,任选地包含其他杂原子,例如N,O或S;或Y 1> F,Cl,Br,I,N 3,CN,CH 2 NRY3RY4,CH 2 OH,CH 2 ORY 3,CH 2 SRY 4,SCN,芳基或杂芳基; RY3,RY4:R23;或NRY3RY4:4-8元杂环烷基环,任选地包含另外的杂原子,例如N,O或S;或W 1> O,S,NH或N-R81; R81,R51:R5中的任一个;或NR81R51:4-8元杂环烷基环,任选地含有其他杂原子,例如N,O或S;或Z:O,S或NR 9; R 9:H或1-6C烷基。 [图像] [图像]活动:细胞静止;抗寄生虫;免疫抑制消炎(药;具有神经保护作用。作用机理:拓扑异构酶I抑制剂;拓扑异构酶II抑制剂。在乳腺癌细胞(MCF7)中测试了(I)的细胞毒性作用。结果表明(I)显示出0.19μM的中值抑制浓度。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号